Search

Your search keyword '"Yoshiyuki Yazaki"' showing total 6 results
Start Over Author "Yoshiyuki Yazaki" Language english
6 results on '"Yoshiyuki Yazaki"'

1. Ethnic differences in association of outcomes with trimethylamine N‐oxide in acute heart failure patients

Author

Yoshiyuki Yazaki, Kenichi Aizawa, Muhammad Zubair Israr, Keita Negishi, Andrea Salzano, Yuka Saitoh, Natsuka Kimura, Ken Kono, Liam Heaney, Shabana Cassambai, Dennis Bernieh, Florence Lai, Yasushi Imai, Kazuomi Kario, Ryozo Nagai, Leong L. Ng, and Toru Suzuki

Subjects
Heart failure, Ethnicity, TMAO, Gut metabolite, Outcomes, Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract

Abstract Aims The aim of this study was to investigate whether ethnicity influences the associations between trimethylamine N‐oxide (TMAO) levels and heart failure (HF) outcomes. Methods and results Trimethylamine N‐oxide levels were measured in two cohorts with acute HF at two sites. The UK Leicester cohort consisted mainly of Caucasian (n = 842, 77%) and South Asian (n = 129, 12%) patients, whereas patients in the Japanese cohort (n = 116, 11%) were all Japanese. The primary endpoint was the measurement of all‐cause mortality and/or HF rehospitalization within 1 year post‐admission. Association of TMAO levels with outcome was compared in the entire population and between ethnic groups after adjustment for clinical parameters. TMAO levels were significantly higher in Japanese patients [median (interquartile range): 9.9 μM (5.2–22.8)] than in Caucasian [5.9 μM (3.6–10.8)] and South Asian [4.5 μM (3.1–8.4)] (P

Published
2020
Full Text
View/download PDF

2. Association with outcomes and response to treatment of trimethylamine N-oxide in heart failure (from BIOSTAT-CHF)

Author

Piotr Ponikowski, Dirk J. van Veldhuisen, Stefan D. Anker, Leong L. Ng, Daniel C. S. Chan, Gerasimos Filippatos, Marco Metra, Chim C. Lang, Donald J. L. Jones, Yoshiyuki Yazaki, Kenneth Dickstein, Faiez Zannad, Aeilko H. Zwinderman, Nilesh J. Samani, John G.F. Cleland, Hans L. Hillege, Toru Suzuki, Adriaan A. Voors, Epidemiology and Data Science, APH - Methodology, Cardiovascular Centre (CVC), Life Course Epidemiology (LCE), and Groningen Kidney Center (GKC)

Subjects
Male, 0301 basic medicine, medicine.medical_specialty, Medication Therapy Management, medicine.drug_class, Trimethylamine N-oxide, Heart failure, Metabolite, 030204 cardiovascular system & hematology, Risk Assessment, Gastroenterology, Biomarkers, Pharmacological, Methylamines, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, Natriuretic Peptide, Brain, Outcome Assessment, Health Care, Natriuretic peptide, Humans, Medicine, Adverse effect, Biomarker, Gut microbiome, Outcome study, business.industry, NATRIURETIC PEPTIDE, MORTALITY, Hazard ratio, Guideline, Middle Aged, medicine.disease, Confidence interval, 3. Good health, Europe, PROGNOSTIC VALUE, Observational Studies as Topic, 030104 developmental biology, chemistry, HOSPITALIZATION, Disease Progression, SURVIVAL, Biomarker (medicine), Female, Cardiology and Cardiovascular Medicine, business
Abstract

Aims: Association of elevated circulating levels of trimethylamine N-oxide (TMAO) with adverse outcomes in patients with heart failure (HF) has been described. However, response of TMAO levels to treatment and medications has not been investigated. Therefore, we investigated whether TMAO levels are responsive to guideline-recommended treatment and medications, and further reflect changes in outcomes. Methods and results: TMAO levels were investigated in the systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure (BIOSTAT-CHF), which addressed response to guideline-recommended pharmacological treatment. TMAO levels in 2234 patients with new-onset or progressively worsening HF showed strong associations with adverse events (mortality and/or rehospitalisation) at 1, 2 and 3 years [hazard ratio (HR) 1.37–1.51, P ≤ 0.019). Analysis of 972 patients with plasma available at both enrolment and follow-up visit showed reductions of B-type natriuretic peptide (BNP) levels with guideline-based treatment (P < 0.001), but not for TMAO levels. Moreover, patients with higher TMAO levels than median before and after treatment showed increased association with adverse outcomes [HR 2.21, 95% confidence interval (CI) 1.43–3.43, P < 0.001] compared to patients with lower than median levels either before or after treatment (HR 1.13, 95% CI 0.63–2.04, P = 0.684 and HR 1.14, 95% CI 0.64–2.03, P = 0.662, respectively). Conclusion: TMAO levels were associated with adverse outcomes (mortality and/or rehospitalisation) in BIOSTAT-CHF, and did not respond to guideline-based pharmacological treatment in contrast to BNP levels which did as expected. Lower TMAO levels were associated with favourable outcome regardless of treatment.

Published
2019

4. Clinical Outcomes of Rivaroxaban Monotherapy in Heart Failure Patients With Atrial Fibrillation and Stable Coronary Disease: Insights From the AFIRE Trial.

Author

Yoshiyuki Yazaki, Masato Nakamura, Raisuke Iijima, Satoshi Yasuda, Koichi Kaikita, Masaharu Akao, Junya Ako, Tetsuya Matoba, Katsumi Miyauchi, Nobuhisa Hagiwara, Kazuo Kimura, Atsushi Hirayama, Kunihiko Matsui, Hisao Ogawa, Yazaki, Yoshiyuki, Nakamura, Masato, Iijima, Raisuke, Yasuda, Satoshi, Kaikita, Koichi, and Akao, Masaharu

Subjects
*ATRIAL fibrillation, *CORONARY disease, *HEART failure patients, *TREATMENT effectiveness, *RIVAROXABAN, *RESEARCH, *RESEARCH methodology, *ANTICOAGULANTS, *MEDICAL cooperation, *EVALUATION research, *COMPARATIVE studies, *CORONARY artery disease, *HEART failure, *PHARMACODYNAMICS
Published
2021
Full Text
View/download PDF

5. Relationship between renal function stage and clinical outcomes after paclitaxel-eluting stent implantation

Author

Masato Nakamura, Yoshiyuki Yazaki, Kaoru Sugi, and Raisuke Iijima

Subjects
Male, medicine.medical_specialty, Paclitaxel, medicine.medical_treatment, Renal function, Coronary Disease, urologic and male genital diseases, Percutaneous coronary intervention, Internal medicine, Chronic kidney disease, medicine, Humans, Dialysis, Aged, business.industry, Stent, Drug-Eluting Stents, medicine.disease, Antineoplastic Agents, Phytogenic, Treatment Outcome, Drug-eluting stent, Major adverse cardiovascular events, Conventional PCI, Cardiology, Kidney Failure, Chronic, Female, Glomerular filtration rate, business, Cardiology and Cardiovascular Medicine, Mace, Kidney disease, Follow-Up Studies
Abstract

Summary Background: Chronic kidney disease (CKD) is associated with poor outcomes after percutaneous coronary intervention (PCI). This study aimed to evaluate the relationship between the degree of renal function at baseline and long-term clinical outcomes in coronary artery disease patients who underwent paclitaxel-eluting stent implantation. Methods: A total of 336 patients with 400 de-novo lesions underwent PCI between May 2007 and March 2009. The patients were divided into 4 groups: control (glomerular filtration rate (GFR) 90 ml/min; n = 132); mild CKD (GFR 60—89 ml/min; n = 112); moderate CKD (GFR

Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results